Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

Trial Details

NCT ID

NCT07156253

Phase

PHASE1

Sponsor

Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

• SYN818 and Olaparib will be administered

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806
• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• Having signed the written Informed Consent Form (ICF);
• Male or female aged ≥18 years;
• Life expectancy ≥12 weeks;
• Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.